Brief: Gensight Biologics End-March Cash And Cash Equivalents At EUR 61.1 Mln

Gensight Biologics SA

20/04/2021 06:30

April 20 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * END-MARCH CASH AND CASH EQUIVALENTS EUR 61.1 MILLION,
COMPARED
TO EUR 37.9 MILLION AS OF DECEMBER 31, 2020
    * WE ENTER FINAL STRETCH OF LUMEVOQ’S REGISTRATION PHASE IN
VERY
STRONG FINANCIAL POSITION-CEO
    * Q1 REVENUES FROM SALE OF LUMEVOQ UNDER ATU IN FRANCE EUR
3.9
MILLION VERSUS EUR 0.7 MILLION YEAR AGO

Source text for Eikon:  ID:nBw3Mwxsya 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))